Erythroid Cell Protein Retention via Ubiquitination Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic proteins or polypeptides, such as enzyme replacement therapy, face challenges in maintaining high bioavailability and avoiding immune responses, with techniques like hypotonic lysis compromising cell membrane integrity and requiring frequent transfusions, and global ubiquitination inhibition disrupting cell function.
Innovation Solution
A method that involves configuring or inhibiting target proteins or polypeptides to hinder ubiquitination during erythroid cell maturation, allowing elevated concentrations to be retained in reticulocytes and erythrocytes, using genetic modification and specific inhibitors to prevent ubiquitin-mediated degradation without affecting ubiquitin ligases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If hypotonic lysis is used to encapsulate protein in erythrocytes, then protein delivery is achieved, but cell membrane integrity is compromised and frequent transfusions are required
Solution Approach 1:
The patent changes the osmotic parameters from hypotonic to isotonic conditions during erythrocyte preparation. By using isotonic saline instead of hypotonic solution, the cell membrane integrity is preserved while still allowing protein encapsulation through a modified lysis-rescaling process that maintains cellular structure and reduces the need for frequent transfusions.
2Quantity of substance
If global ubiquitination inhibition is used to prevent protein degradation, then protein retention is improved, but cell function is disrupted
Solution Approach 1:
The patent applies local quality by using a peptide sequence specifically targeted to the ubiquitination site on the therapeutic protein, rather than globally inhibiting ubiquitination. This localized approach prevents degradation of the specific therapeutic protein while leaving other cellular ubiquitination processes unaffected, thus maintaining normal cell function.
Solution Approach 2:
The patent introduces a peptide sequence as an intermediary that binds to the ubiquitination site on the therapeutic protein. This peptide acts as a mediator that blocks ubiquitin ligases from degrading the therapeutic protein, providing specific protection without disrupting overall cellular ubiquitination machinery.
3Reliability
If genetic engineering is used to express enzyme in erythroid progenitors, then cell membrane integrity is retained, but protein expression must occur before enucleation
Solution Approach 1:
The patent applies preliminary action by introducing the therapeutic protein or peptide sequence into the erythroid progenitor cells before enucleation occurs. The protein is expressed and functional during the nucleated stage, and then the cell completes maturation and enucleation with the therapeutic protein already in place and active, eliminating the timing constraint.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the retention and abundance of therapeutic proteins in erythroid cells, reducing the need for frequent transfusions and minimizing immune responses, while maintaining cell membrane integrity and function.
Implementation Method 1
during maturation of the erythroid progenitor into the reticulocyte, the target protein or polypeptide is configured and/or inhibited such that ubiquitination of the target protein or polypeptide is hindered or prevented
Data Source
AI summary
A method of making an erythroid cell comprising elevated levels of a target protein or polypeptide, the method comprising: a) provision of an erythroid progenitor which is able to express the target protein or polypeptide; b) expression of the target protein or polypeptide; and c) maturation of the erythroid progenitor into the erythroid cell; wherein during maturation of the erythroid progenitor into the erythroid cell, the target protein or polypeptide is configured and/or inhibited such that ubiquitination of the target protein or polypeptide is hindered or prevented. Erythroid cells, pharmaceutical compositions and methods of use related thereto, and a method of screening for proteins or polypeptides degraded by ubiquitination during maturation of an erythroid progenitor are also provided.